{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:11Z","timestamp":1740134891430,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"DOI":"10.1182\/blood.2023023758","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:30:40Z","timestamp":1713454240000},"page":"1558-1559","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Ibrutinib in CLL: benefit for all?"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-1308","authenticated-orcid":false,"given":"Antonio","family":"Cuneo","sequence":"first","affiliation":[{"name":"1University of Ferrara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"2Universit\u00e0 Vita-Salute San Raffaele"},{"name":"3Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"16","key":"2024041815303466000_bib1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"22","key":"2024041815303466000_bib2","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1002\/cam4.3470","article-title":"Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study","volume":"9","author":"Cuneo","year":"2020","journal-title":"Cancer Med"},{"unstructured":"Munir\n              T\n            , ShadmanM, RobakT, . Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients with treatment na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study [abstract]. Abstract book EHA 2023. Abstract 639. Accessed 29 November 2023. https:\/\/journals.lww.com\/hemasphere\/Documents\/EHA2023%20Abstract%20Book.pdf.","key":"2024041815303466000_bib3"},{"issue":"1","key":"2024041815303466000_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/hematology.2022000343","article-title":"Selecting initial therapy in CLL","volume":"2022","author":"Ahn","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2024041815303466000_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-023-00865-z","article-title":"Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency","volume":"13","author":"Rigolin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024041815303466000_bib6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2024041815303466000_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2023-181774","article-title":"Impact of ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma [abstract]","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024041815303466000_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2024041815303466000_bib9","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2017007294","article-title":"Patients\u2019 priorities in selecting chronic lymphocytic leukemia treatments","volume":"1","author":"Mansfield","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2024041815303466000_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMp2301257","article-title":"At breaking point or already broken? The National Health Service in the United Kingdom","volume":"389","author":"Hunter","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/16\/1558\/2222261\/blood_bld-2023-023758-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/16\/1558\/2222261\/blood_bld-2023-023758-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:30:45Z","timestamp":1713454245000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/16\/1558\/515701\/Ibrutinib-in-CLL-benefit-for-all"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":10,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,4,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023758","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}